BioinvestGPT ApS · Research use only
Case study · Aficamten vs mavacamten in non-obstructive HCM ·
BVCT called mavacamten (No. 1959) on : partial SUCCESS (statistically maybe significant yet weak clinical benefit in KCCQ compared with placebo). ODYSSEY-HCM failed (; True Negative (TN)). Aficamten (No. 2094), called : SUCCESS (statistically significant clinical benefit in KCCQ CSS compared with placebo). ACACIA-HCM succeeded (topline ; True Positive (TP)).
Ten-Billion-Dollar Differential Effect Sizes—Predicted in advance by BVCT—Directly From A Few Atoms’ Differences.
Mavacamten fails (No. 1959). Aficamten succeeds (No. 2094).
Non-obstructive HCM. Predicted from atoms alone.
Same indication: symptomatic non-obstructive HCM. Same drug class: cardiac myosin inhibitor. Same primary endpoint: KCCQ-CSS (one of two in each trial). Two molecules, two phase-3 trials, opposite outcomes — and BeatSoC Virtual Clinical Trials (BVCTs) called both, ex ante, from molecular differences alone.
12 days in advance: BVCT Prediction No. 1959 — mavacamten in non-obstructive HCM, recorded technical call partial SUCCESS (statistically maybe significant yet weak clinical benefit in KCCQ compared with placebo). ODYSSEY-HCM failed its primary endpoints. The dashboard classifies the readout as True Negative (TN).
170 days in advance: BVCT Prediction No. 2094 — aficamten will succeed in non-obstructive HCM, recorded technical call SUCCESS (statistically significant clinical benefit in KCCQ CSS compared with placebo). ACACIA-HCM confirmed it: Cytokinetics announced positive topline results on ; the dashboard classifies the readout as True Positive (TP).
The atoms differ. The clinical outcome differs. BVCT closes the loop.
| Mavacamten · BVCT No. 1959 | Aficamten · BVCT No. 2094 | |
|---|---|---|
| Molecule | C15H19N3O2 + SMILES | C18H19N5O2 + SMILES |
| BVCT call (ex-ante), as recorded | Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in KCCQ compared with placebo). Commercial: partial SUCCESS (commercially maybe sufficient yet weak clinical benefit in KCCQ moderately inferior to aficamten). | Technical: SUCCESS (statistically significant clinical benefit in KCCQ CSS compared with placebo). Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in KCCQ CSS numerically-to-slightly superior to metoprolol). |
| Timestamped | on (12 days before readout) | on (170 days before readout) |
| Phase-3 trial | ODYSSEY-HCM (BMS). | ACACIA-HCM (NCT06081894, CYTK). |
| Readout & verdict | Failed both primary endpoints. True Negative (TN). | KCCQ-CSS +3.0 (p=0.021); pVO2 +0.67 mL/kg/min (p=0.003). True Positive (TP). |
BVCT maps each molecular difference — atom-level structure, SMILES — through the full virtual body of non-obstructive HCM, all the way to the differential clinical effect size on KCCQ-CSS. No clinical history. No PK/PD modelling. No analogue-drug regression. The atoms go in; the placebo-adjusted KCCQ-CSS delta comes out, at 0.1 HR precision, with a mechanistic causal rationale per call.
Mavacamten was the lead asset of BMS's $13.1B MyoKardia acquisition. The non-obstructive HCM expansion was a major growth driver. ODYSSEY-HCM failed; that expansion value was lost. In our view, calling that ahead of the trial would have changed billion-dollar capital, M&A and portfolio decisions.
Aficamten now sits at the centre of Cytokinetics' multi-billion-dollar valuation. ACACIA-HCM was the gating event for non-obstructive HCM peak sales, conservatively estimated at $1–3B/year. Knowing it would succeed, 170 days early, de-risks, in our estimate, around half a billion in clinical investment and unlocks multi-billion-dollar partnership and BD options.
Conservatively, BVCT has proven a $3–5 billion decision capability for this single drug pair, this single indication.
Now multiply by every drug, every indication, every pivotal trial in pharma's pipeline.
See No. 1959 (ODYSSEY-HCM) and No. 2094 (ACACIA-HCM) on the dashboard.
SEQUOIA-HCM · obstructive HCM · aficamten versus placebo
MAPLE-HCM · obstructive HCM · aficamten head-to-head versus metoprolol succinate
Start at bvct.bioinvestgpt.com →
Clinical foresight before decisions. Earlier BVCT is kinder for patients.